Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain

Launched by FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO · Mar 29, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the causes of low back pain, particularly those linked to a condition called intervertebral disc degeneration. This condition affects the discs in the spine, leading to pain and other health issues for many people. The researchers want to explore a specific group of molecules called sphingolipids, which may play a role in the inflammation and pain associated with disc degeneration. By studying these molecules, they hope to find new ways to identify and treat this common problem.

If you have been diagnosed with disc degeneration due to conditions like spondylolisthesis or a herniated disc, you may be eligible to participate in this trial. Participants will have the opportunity to contribute to important research that could lead to better treatments for back pain. It’s important to note that patients with spinal infections cannot join the study. Overall, this trial aims to deepen our understanding of disc degeneration and its impact on pain, potentially leading to new therapeutic options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with disc degeneration for spondylolisthesis, herniated intervertebral disc, and other causes of disc degeneration
• Exclusion Criteria:
• • Spinal infection